Cancer epidemiology · 2026
Association between L-α-glycerylphosphorylcholine use and risk of kidney cancer: A nationwide representative retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Young Jun, Yu Jiwon, Kang Ju Hyun, Park Sun Jae, Jeong Seogsong, Lee Gyeongsil, Shin Hyun-Young, Park Sang Min
Аннотация
BACKGROUND: L-α-glycerylphosphorylcholine (α-GPC) is widely prescribed for cognitive impairment and Alzheimer's dementia. Previous cohort studies have reported that dietary free choline intake was associated with decreased kidney cancer risk. The oncologic safety of supplemental α-GPC remains uncertain given its role in producing trimethylamine N-oxide (TMAO), a metabolite implicated in renal injury and certain malignancies. This study aimed to test the hypothesis whether α-GPC use was associated with the reduction of incident kidney cancer.
METHODS: Using the Korean National Health Insurance Service database, we conducted a nationwide retrospective cohort study among adults aged ≥ 50 who underwent health screening in 2009-2010. After exclusion criteria and 1:5 exact propensity score matching, 81,970 α-GPC users and 409,801 non-users were analyzed using Cox proportional hazards models. Incident kidney cancer events were identified from 2011 to 2024.
RESULTS: α-GPC use was not associated with kidney cancer risk (adjusted HR 0.95, 95% CI 0.84-1.08; 280 events in α-GPC users, 1570 in non-users). Results were consistent across lag-time sensitivity analyses and subgroup analyses by age, sex, income, Charlson comorbidity index, and estimated glomerular filtration rate.
CONCLUSIONS: α-GPC use was not associated with incident kidney cancer in this large Korean cohort. Further studies in diverse populations are warranted in order to confirm these findings.
METHODS: Using the Korean National Health Insurance Service database, we conducted a nationwide retrospective cohort study among adults aged ≥ 50 who underwent health screening in 2009-2010. After exclusion criteria and 1:5 exact propensity score matching, 81,970 α-GPC users and 409,801 non-users were analyzed using Cox proportional hazards models. Incident kidney cancer events were identified from 2011 to 2024.
RESULTS: α-GPC use was not associated with kidney cancer risk (adjusted HR 0.95, 95% CI 0.84-1.08; 280 events in α-GPC users, 1570 in non-users). Results were consistent across lag-time sensitivity analyses and subgroup analyses by age, sex, income, Charlson comorbidity index, and estimated glomerular filtration rate.
CONCLUSIONS: α-GPC use was not associated with incident kidney cancer in this large Korean cohort. Further studies in diverse populations are warranted in order to confirm these findings.